Novavax (NVAX) Akcie Kurz
Novavax Kurz
Tržby rostly o 33,4 % ročně za posledních 19 let na 1,12 Mld. USD. čistá marže společnosti Novavax je nyní 39,2 %, nahoru z -152,1 % před několika lety. Medián cílové ceny analytiků je 18,00 USD, tedy nad aktuální cenu o 67,0 %. Z 15 analytiků jich 10 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Novavax
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Novavax a analýza akcií
Nejčastější otázky týkající se akcie Novavax
Novavax Inc is primarily active within the biotechnology and pharmaceutical industries.
The main competitors of Novavax Inc in the market are companies like Moderna, Pfizer, and Johnson & Johnson.
The business model of Novavax Inc revolves around developing innovative vaccines to address infectious diseases. Novavax is a biotechnology company that focuses on the discovery, development, and commercialization of vaccines for various viral infections. With a particular focus on respiratory diseases, including influenza and respiratory syncytial virus (RSV), Novavax utilizes cutting-edge technologies to create vaccines that stimulate protective immune responses. The company's approach includes the use of recombinant nanoparticle vaccine technology, which enables the production of vaccine antigens that closely mimic targeted viruses. Novavax strives to provide advanced vaccine solutions to combat prevalent and emerging infectious diseases worldwide.
Novavax Inc. is a leading biotechnology company focused on the development of innovative vaccines. Founded in 1987, Novavax has a rich history of scientific excellence and groundbreaking research. The company is committed to addressing urgent global health challenges and has made significant advancements in the field of vaccine development. Novavax has pioneered the use of recombinant nanoparticle vaccine technology and has successfully produced vaccine candidates for a range of infectious diseases, including respiratory syncytial virus (RSV), influenza, and COVID-19. With its strong research capabilities and dedicated team, Novavax continues to strive for transformative solutions in public health through its pioneering vaccine technologies.
Novavax Inc has achieved several significant milestones. One of the key achievements includes the development of a proprietary recombinant nanoparticle vaccine technology platform called Matrix-M. This innovative platform has facilitated the creation of multiple vaccine candidates targeting viral diseases. Novavax Inc has also successfully conducted clinical trials and achieved positive results for various vaccines, including those targeting respiratory syncytial virus (RSV) and influenza. Furthermore, the company has collaborated with renowned organizations, such as the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation, demonstrating its recognition and partnerships within the industry.
Novavax Inc is primarily present in multiple countries and regions. The company has a global presence and operates in various key markets. Some of the primary countries and regions where Novavax Inc is actively engaged include the United States, United Kingdom, Canada, Europe, and Australia. With its innovative and cutting-edge approach to vaccine development, Novavax Inc aims to offer its healthcare solutions to a wide range of international markets. The company's commitment to expanding its presence ensures that its groundbreaking medical technologies reach people across different countries and regions, fostering better health outcomes worldwide.
Novavax Inc represents values of innovation, dedication, and collaboration in the biotechnology industry. With a corporate philosophy focused on developing novel vaccines to prevent infectious diseases, Novavax aims to improve global health outcomes. Their commitment to scientific excellence and rigorous research enables them to address evolving public health challenges. Novavax Inc strives to make a positive impact by developing safe and effective vaccines, leveraging their technological expertise and diverse partnerships. Through their tireless efforts, Novavax Inc aims to provide innovative solutions to protect communities worldwide, solidifying their position as a leading biotech company.
Analytici aktuálně stanovují průměrnou cílovou cenu 18,00 USD pro akcii Novavax (medián: 18,00 USD), tedy +67,0 % vůči poslední ceně. Konsensus vychází z 15 hodnocení analytiků.
15 analytiků aktuálně hodnotí akcii Novavax: 10 doporučuje koupit, 2 držet a 3 prodat. Pro rok 2026 analytici očekávají u Novavax tržby 377,50 Mil. USD a zisk na akcii -0,52 USD.
Při aktuálním kurzu se akcie Novavax obchoduje za 9,67 EUR (10,78 USD).
Akcie Novavax (NVAX) je kótována na 8 burzách, mimo jiné: NASDAQ (NVAX), London (0A3S.L), SIX (Zürich) (NVV1.SW), XETRA (NVV1.F), München (NVV1.MU), Düsseldorf (NVV1.DU), Hamburg (NVV1.HM).
Novavax Inc. is a biopharmaceutical company specializing in the development of innovative vaccines and treatments for a variety of infectious diseases. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland, USA.
Tržby očekávané za Novavax činí 377,50 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Novavax činí -90,29 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Novavax je aktuálně -20,67. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Novavax.
Poměr ceny k tržbám (P/S) Novavax je aktuálně 4,94. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Novavax.
Score kvality pro Novavax je 5/10.
ISIN Novavax je US6700024010. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Novavax je A2PKMZ. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Novavax je NVAX. Symbol tickeru se používá k obchodování akcií Novavax na burze.
Novavax akcie
Novavax Ticker
Novavax FIGI
Všechny fundamentální údaje o Novavax v podrobné analýze
Naše analýzy akcií společnosti Novavax zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Novavax. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: